Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Olaparib · 1 trial · 3 indications
over the total number of patients in a given cohort.
| Arm | Type | Description |
|---|---|---|
| Group 1 - Arm CLOSED, no patients recruited | EXPERIMENTAL | VEGFR1, VEGFR2, VEGFR3 |
| Group 2 - Arm CLOSED, no patients recruited | EXPERIMENTAL | BCR-ABL, SRC |
| Group 3 - Arm CLOSED | EXPERIMENTAL | ALK, ROS1, MET |
| Group 4 - Arm CLOSED, no patients recruited | EXPERIMENTAL | KIT, PDGFRA, PDGFRB, ABL1 |
| Group 5 - Arm CLOSED | EXPERIMENTAL | EGFR |
| Group 6 - Arm CLOSED | EXPERIMENTAL | high mutation burden, POLE, POLD1 |
| Group 7 - Arm CLOSED | EXPERIMENTAL | BRCA1, BRCA2, mutations in HRD |
| Group 8 - Arm CLOSED | EXPERIMENTAL | CDKN2A, CDK4, CCND1, SMARCA4 |
| Group 9 Arm CLOSED | EXPERIMENTAL | CSF1R, PDGFRA, PDGFRB,VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, RET, FGFR1, FGFR2, FGFR3, VHL |
| Group 10 Arm CLOSED | EXPERIMENTAL | AKT1, AKT2, AKT3, FBXW7, FLCN, mTOR, NF1, NF2, NTRK3, PIK3CA, PIK3R1, PTEN, RHEB, STK11, TSC1, TSC2 |
| Group 11 - Arm CLOSED | EXPERIMENTAL | ERBB2 |
| Group 12 - Arm CLOSED | EXPERIMENTAL | BRAFV600 |
| Group 13 - Arm CLOSED | EXPERIMENTAL | PTCH1, SMO |
| Group 14 | EXPERIMENTAL | ERBB2 |
| Name | Type | Description |
|---|---|---|
| Olaparib | DRUG | 300mg taken twice daily |
| Dasatinib | DRUG | 100mg administered orally once daily |
| Nivolumab plus Ipilimumab | DRUG | * Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase. * Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks. |
| Axitinib | DRUG | 5mg orally twice daily |
| Bosutinib | DRUG | 500mg orally once daily |
| Crizotinib | DRUG | 250mg orally twice daily |
| Palbociclib | DRUG | 125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days |
| Sunitinib | DRUG | 50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off |
| Temsirolimus | DRUG | 25mg infused over a 30-60 minute period once a week |
| Erlotinib | DRUG | 150mg orally, once daily |
| Trastuzumab plus Pertuzumab | DRUG | Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion. Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes. |
| Vemurafenib plus Cobimetinib | DRUG | Vemurafenib = 960 mg orally every 12 hours. Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest |
| Vismodegib | DRUG | 150mg taken orally, once daily |
| Tucatinib | DRUG | 300mg taken orally, twice daily |
Inclusion Criteria: (screening step - non-drug specific) * Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid tumour (excluding primary brain tumours), multiple myeloma or B cell non-Hodgkin lymphoma (excluding CLL, SLL and HCL), for whom there is no standard treatment...
Olaparib is being studied for the treatment of lymphoma, including non-Hodgkin lymphoma, as part of an ongoing clinical trial. It is an investigational small molecule in Phase 2 development for this indication. The drug is also being evaluated in other advanced solid tumors and multiple myeloma within the same trial.
Olaparib is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with lymphoma and other advanced cancers.
Olaparib belongs to the PARP inhibitor class of drugs, which target poly (ADP-ribose) polymerase enzymes. These enzymes are involved in DNA repair, and inhibiting them can affect cancer cell survival. The drug is being investigated for its potential role in treating lymphoma and other malignancies.
Olaparib is currently in Phase 2 clinical development for the treatment of lymphoma, including non-Hodgkin lymphoma. The drug is investigational and has not yet been approved for this indication. It is being evaluated in an ongoing clinical trial that is actively recruiting participants.
Olaparib is being studied in clinical trial NCT03297606, titled "Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)." This Phase 2 trial is recruiting 720 participants in Canada and includes patients with non-Hodgkin lymphoma, multiple myeloma, and advanced solid tumors. The trial is open to adults aged 18 years and older.
Olaparib is a PARP inhibitor, a class of drugs that includes other agents with similar mechanisms of action. However, olaparib is a distinct drug compound developed by Pfizer. Its specific chemical structure and clinical profile differentiate it from other PARP inhibitors, though they share a common target.